Zacks Research Issues Positive Estimate for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Zacks Research increased their Q4 2024 earnings per share estimates for Corcept Therapeutics in a research report issued to clients and investors on Wednesday, November 20th. Zacks Research analyst K. Das now anticipates that the biotechnology company will post earnings of $0.28 per share for the quarter, up from their previous estimate of $0.26. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q3 2025 earnings at $0.41 EPS, Q4 2025 earnings at $0.52 EPS, FY2025 earnings at $1.56 EPS, Q3 2026 earnings at $0.70 EPS and FY2026 earnings at $2.38 EPS.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.14. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The company had revenue of $182.55 million during the quarter, compared to analyst estimates of $171.97 million. During the same quarter in the prior year, the business earned $0.28 earnings per share. The firm’s revenue for the quarter was up 47.7% on a year-over-year basis.

A number of other research analysts have also weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Corcept Therapeutics in a research note on Thursday, October 31st. Truist Financial raised their price objective on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the company a “buy” rating in a research report on Monday, September 30th. Canaccord Genuity Group reissued a “buy” rating and issued a $38.00 price target on shares of Corcept Therapeutics in a report on Tuesday, July 30th. Piper Sandler upped their target price on Corcept Therapeutics from $38.00 to $67.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 18th. Finally, Sandler O’Neill restated a “buy” rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $65.25.

Corcept Therapeutics Price Performance

CORT opened at $55.91 on Friday. The company has a market capitalization of $5.86 billion, a price-to-earnings ratio of 44.37 and a beta of 0.45. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $47.62 and a 200-day moving average price of $37.52. Corcept Therapeutics has a twelve month low of $20.84 and a twelve month high of $61.66.

Hedge Funds Weigh In On Corcept Therapeutics

Hedge funds have recently made changes to their positions in the business. Capital Performance Advisors LLP purchased a new position in Corcept Therapeutics during the 3rd quarter valued at $25,000. Park Place Capital Corp purchased a new position in shares of Corcept Therapeutics during the second quarter valued at about $32,000. Atwood & Palmer Inc. bought a new position in Corcept Therapeutics in the second quarter worth about $35,000. Kathleen S. Wright Associates Inc. purchased a new stake in Corcept Therapeutics in the third quarter worth about $36,000. Finally, Blue Trust Inc. boosted its position in Corcept Therapeutics by 125.4% during the 2nd quarter. Blue Trust Inc. now owns 3,526 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 1,962 shares in the last quarter. 93.61% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Corcept Therapeutics news, insider Gary Charles Robb sold 3,101 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $35.71, for a total transaction of $110,736.71. Following the completion of the sale, the insider now directly owns 23,190 shares in the company, valued at $828,114.90. This represents a 11.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.88, for a total value of $131,736.00. The disclosure for this sale can be found here. Insiders sold a total of 36,301 shares of company stock valued at $1,594,253 over the last 90 days. Insiders own 20.50% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.